| Larry D Mckenzie, DO | |
|
4716 W Urbana St Ste 200, Broken Arrow, OK 74012-6162 | |
| (918) 710-4112 | |
| (918) 710-4118 |
| Full Name | Larry D Mckenzie |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 32 Years |
| Location | 4716 W Urbana St Ste 200, Broken Arrow, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003875212 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Francis Hospital Vinita, Inc | Vinita, OK | Hospital |
| Saint Francis Hospital Muskogee | Muskogee, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Access Pain Solutions | 2668620220 | 13 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.
A possible 'first-line' treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Dutch researchers report that weather conditions including temperature, sunshine, and precipitation have no impact on fibromyalgia symptoms in female patients. Results published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), suggest that individual patients may be sensitive to some changes in the weather.
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
A unique nationwide patient safety project funded by the Agency for Healthcare Research and Quality (AHRQ) reduced the rate of central line-associated bloodstream infections (CLABSIs) in intensive care units by 40 percent, according to the agency's preliminary findings of the largest national effort to combat CLABSIs to date.
› Verified 1 days ago
| Entity Name | Ctca Physicans Group Of Oklahoma, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053309591 PECOS PAC ID: 2163328774 Enrollment ID: O20031212000074 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.
A possible 'first-line' treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Dutch researchers report that weather conditions including temperature, sunshine, and precipitation have no impact on fibromyalgia symptoms in female patients. Results published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), suggest that individual patients may be sensitive to some changes in the weather.
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
A unique nationwide patient safety project funded by the Agency for Healthcare Research and Quality (AHRQ) reduced the rate of central line-associated bloodstream infections (CLABSIs) in intensive care units by 40 percent, according to the agency's preliminary findings of the largest national effort to combat CLABSIs to date.
› Verified 1 days ago
| Entity Name | Access Pain Solutions |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740535368 PECOS PAC ID: 2668620220 Enrollment ID: O20120924000708 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.
A possible 'first-line' treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Dutch researchers report that weather conditions including temperature, sunshine, and precipitation have no impact on fibromyalgia symptoms in female patients. Results published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), suggest that individual patients may be sensitive to some changes in the weather.
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
A unique nationwide patient safety project funded by the Agency for Healthcare Research and Quality (AHRQ) reduced the rate of central line-associated bloodstream infections (CLABSIs) in intensive care units by 40 percent, according to the agency's preliminary findings of the largest national effort to combat CLABSIs to date.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Larry D Mckenzie, DO 4716 W Urbana St Ste 200, Broken Arrow, OK 74012-6162 Ph: (918) 710-4112 | Larry D Mckenzie, DO 4716 W Urbana St Ste 200, Broken Arrow, OK 74012-6162 Ph: (918) 710-4112 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.
A possible 'first-line' treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Dutch researchers report that weather conditions including temperature, sunshine, and precipitation have no impact on fibromyalgia symptoms in female patients. Results published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), suggest that individual patients may be sensitive to some changes in the weather.
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
A unique nationwide patient safety project funded by the Agency for Healthcare Research and Quality (AHRQ) reduced the rate of central line-associated bloodstream infections (CLABSIs) in intensive care units by 40 percent, according to the agency's preliminary findings of the largest national effort to combat CLABSIs to date.
› Verified 1 days ago
Dr. Joshua J. Livingston, D.O. Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 2033 W Houston St, Broken Arrow, OK 74012 Phone: 918-743-3636 Fax: 918-743-3663 |